Independent · Data-Driven · Trustworthy
PeptidePub is the Wirecutter of weight loss peptides — clear, evidence-based reviews of semaglutide, tirzepatide, and retatrutide, with no pharmaceutical sponsorships or conflicts of interest.
Not sure where to start? Get our free Weight Loss Peptide Comparison Chart ↓
Educational content only. PeptidePub does not provide medical advice. Consult a qualified healthcare professional before making any health decisions.
Compare semaglutide, tirzepatide, and retatrutide side by side — trial data, dosing, costs, and FDA status in one free chart.
Join 2,000+ readers. Unsubscribe anytime.
GLP-1 and related peptides have transformed obesity medicine. Here's what the evidence actually shows for each one.
GLP-1 receptor agonist
The breakthrough GLP-1 drug that changed obesity treatment. Extensively studied with 5+ years of clinical data.
GLP-1 + GIP dual agonist
Targets two hunger hormones instead of one, delivering significantly greater weight loss than semaglutide.
GLP-1 + GIP + Glucagon triple agonist
The most powerful weight loss peptide in development. Triple mechanism may approach bariatric surgery outcomes.
Novo Nordisk's higher-dose semaglutide formulation received FDA approval for chronic weight management in adults. The STEP UP trial showed ~21% average weight loss, up from ~15% at the standard 2.4 mg dose.
The FDA approved an oral semaglutide formulation for chronic weight management — a significant step for patients who prefer pills over injections. Previously, Rybelsus was approved only for type 2 diabetes.
Most people regain two-thirds of their lost weight within a year of stopping GLP-1 medications. Here's what the clinical trials show and how to minimize regain.
New research from Munich and Harvard reveals that semaglutide and tirzepatide fundamentally reshape metabolic and inflammatory pathways beyond what weight loss alone can explain.
University of Eastern Finland researchers found semaglutide significantly reduces depression, anxiety, and substance use disorders — effects that go beyond weight loss.
The Trump administration announced deals with Eli Lilly and Novo Nordisk to reduce weight loss drug costs. Here's what we know about TrumpRx and oral semaglutide pricing.
Every claim on PeptidePub is grounded in peer-reviewed research. We cite primary sources, acknowledge the limits of existing evidence, and update content as new data emerges. We are not sponsored by any pharmaceutical company and do not sell peptides or medications.
